Addictive state

Addictive state appears in the book as a pressing but still unsettled frontier for psychedelic treatment. Researchers are investigating whether psychedelic experiences can help people break addictions, while reports describe ibogaine and ayahuasca being used for that purpose beyond conventional clinical research. The account does not present these reports as proof of effectiveness: it instead stresses the difficulty of evaluating treatments in which drug, setting, guidance, and meaning are inseparable.

Addiction as a Treatment Target

The book places addiction alongside depression and cancer-related distress among the conditions prompting renewed inquiry into psychedelic therapy. At the time described, trials were exploring whether psychedelics could help break addictions to alcohol, cocaine, and tobacco. Psilocybin was generally favored over LSD in this new research, in part because it did not carry the same political associations. This is a research agenda, not a report that these treatments had already been established as effective for addiction.

The discussion situates that agenda within the return of clinical research after sanctioned psychedelic therapy ended in the 1970s. Charles Grob describes contemporary researchers as taking up work earlier generations had been forced to leave behind under cultural pressure. Recovering that history, however, does not by itself establish a treatment: earlier findings and new experiments must be assessed according to prevailing scientific standards.

Treatments Beyond the Trial Room

The account also describes practices outside conventional trials. Ibogaine, a psychedelic derived from the root of an African shrub, is being used underground and in clinics in Mexico to treat opiate addiction. Ayahuasca, too, has been reported to help people break addictions. These examples widen the treatment landscape beyond the clinical studies discussed in the book, but the wording remains cautious: the account reports use and claims of benefit rather than presenting controlled evidence or a settled clinical conclusion.

A separate underground network consists of guides and therapists who work with psychedelic substances in carefully prescribed ways, intending to heal illness or support spiritual, creative, and emotional development. The work remains illegal, exposing practitioners to personal and professional risk. Its history reaches back through lineages associated with Timothy Leary, Stanislav Grof, Al Hubbard, and Leo Zeff, whose influence helped transmit practices after legal research had been curtailed. The network is not described as a single formal organization, but its practitioners share methods and inherited knowledge.

Preparation, Guidance, and Safeguards

The guides’ collaborative materials show how underground practice attempts to make a powerful and unpredictable experience more responsible. A draft charter describes widening access to profound experiences, and identifies psychoactive substances as one tool among others, including meditation, breathwork, and fasting. The website also provides legal releases, ethical agreements, and medical questionnaires. Its ethical code places responsibility for the client’s well-being on the guide, emphasizing disclosure of risks, informed consent, confidentiality, safety, and protection against manipulation or self-promotion. It also calls for accommodating clients regardless of their ability to pay.

The accompanying guidelines draw on decades of practice. They address mental and physical preparation, possible drug interactions, intention-setting, the phases of a session, difficult or frightening material, and post-session integration. In the account, these practices matter because treatment is not reduced to swallowing a substance: what happens before, during, and after the session forms part of the therapeutic undertaking. The guide’s conduct and the participant’s expectations are among the conditions through which the experience is organized.

What the Evidence Can and Cannot Establish

The book identifies a central problem for research: psychedelic trials are difficult to blind because participants and guides can often tell whether the participant received the drug or a placebo. Researchers also cannot easily separate the chemical’s effects from set and setting, the therapist’s presence, or the volunteer’s expectations. These complications matter especially when the proposed treatment appears to operate partly by creating an experience, rather than through a narrowly pharmacological effect that can be isolated from its context.

The broader account of psychedelic-assisted psychotherapy offers possible ways to understand such experiences, but it does not supply addiction-specific outcomes. In interviews following a New York University cancer trial, participants described stronger connection to loved ones and a movement from separateness toward interconnectedness; difficult passages could give way to surrender and acceptance. Jeffrey Guss interprets some of these shifts through the drug’s capacity to quiet the ego and loosen rigid patterns of thought. Those findings concern cancer patients, not proof that the same process treats addiction. They nevertheless show why the book treats the therapeutic relationship, expectations, and interpretation as relevant parts of psychedelic care—and why reported promise, clinical investigation, and demonstrated benefit must remain distinct.